JP2010539479A - 月経液、子宮内膜／月経細胞、羊水、臍帯血又は他の試料の感染症検査 - Google Patents
月経液、子宮内膜／月経細胞、羊水、臍帯血又は他の試料の感染症検査 Download PDFInfo
- Publication number
- JP2010539479A JP2010539479A JP2010524888A JP2010524888A JP2010539479A JP 2010539479 A JP2010539479 A JP 2010539479A JP 2010524888 A JP2010524888 A JP 2010524888A JP 2010524888 A JP2010524888 A JP 2010524888A JP 2010539479 A JP2010539479 A JP 2010539479A
- Authority
- JP
- Japan
- Prior art keywords
- sample
- test
- human
- menstrual
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 244
- 230000002175 menstrual effect Effects 0.000 title claims abstract description 161
- 210000004027 cell Anatomy 0.000 title claims abstract description 92
- 210000004700 fetal blood Anatomy 0.000 title claims abstract description 66
- 239000012530 fluid Substances 0.000 title claims abstract description 60
- 210000004381 amniotic fluid Anatomy 0.000 title claims abstract description 45
- 230000002357 endometrial effect Effects 0.000 title claims abstract description 24
- 208000015181 infectious disease Diseases 0.000 claims abstract description 145
- 238000000034 method Methods 0.000 claims abstract description 109
- 241000282414 Homo sapiens Species 0.000 claims abstract description 92
- 210000001124 body fluid Anatomy 0.000 claims abstract description 64
- 239000010839 body fluid Substances 0.000 claims abstract description 60
- 210000004369 blood Anatomy 0.000 claims abstract description 34
- 239000008280 blood Substances 0.000 claims abstract description 34
- 238000012216 screening Methods 0.000 claims abstract description 13
- 208000035473 Communicable disease Diseases 0.000 claims description 99
- 239000000427 antigen Substances 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 64
- 208000006379 syphilis Diseases 0.000 claims description 31
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 30
- 208000002672 hepatitis B Diseases 0.000 claims description 27
- 241000710886 West Nile virus Species 0.000 claims description 21
- 241000701022 Cytomegalovirus Species 0.000 claims description 20
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 18
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 16
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 11
- 208000005176 Hepatitis C Diseases 0.000 claims description 10
- 206010044587 Treponema infections Diseases 0.000 claims description 9
- 208000005252 hepatitis A Diseases 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 7
- 241000223104 Trypanosoma Species 0.000 claims description 5
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 143
- 210000005259 peripheral blood Anatomy 0.000 description 37
- 239000011886 peripheral blood Substances 0.000 description 37
- 238000002835 absorbance Methods 0.000 description 27
- 238000002965 ELISA Methods 0.000 description 26
- 241000711549 Hepacivirus C Species 0.000 description 26
- 241000700721 Hepatitis B virus Species 0.000 description 25
- 238000001514 detection method Methods 0.000 description 25
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 21
- 238000012546 transfer Methods 0.000 description 21
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 20
- 230000008569 process Effects 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- 101710132601 Capsid protein Proteins 0.000 description 18
- 210000003743 erythrocyte Anatomy 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 238000012545 processing Methods 0.000 description 13
- 208000031886 HIV Infections Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 11
- 241000589886 Treponema Species 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 239000003146 anticoagulant agent Substances 0.000 description 11
- 229940127219 anticoagulant drug Drugs 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 239000011324 bead Substances 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 210000004991 placental stem cell Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 238000007689 inspection Methods 0.000 description 8
- 230000008774 maternal effect Effects 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 239000012491 analyte Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000012678 infectious agent Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000003954 umbilical cord Anatomy 0.000 description 7
- 102000004506 Blood Proteins Human genes 0.000 description 6
- 108010017384 Blood Proteins Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108040007629 peroxidase activity proteins Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 238000002669 amniocentesis Methods 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000003169 placental effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000035606 childbirth Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 239000000644 isotonic solution Substances 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000010517 secondary reaction Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000560056 HIV-1 group O Species 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000589910 Treponema phagedenis Species 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 239000003283 colorimetric indicator Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- -1 ethylene potassium tetraacetic acid dipotassium salt Chemical compound 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HKOSYZIBCKCKET-UHFFFAOYSA-M iodotin Chemical compound I[Sn] HKOSYZIBCKCKET-UHFFFAOYSA-M 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99374807P | 2007-09-14 | 2007-09-14 | |
| US19160108P | 2008-09-09 | 2008-09-09 | |
| PCT/US2008/010751 WO2009035706A1 (fr) | 2007-09-14 | 2008-09-15 | Recherche de maladie infectieuse dans du liquide menstruel, des cellules endométriales/menstruelles, du liquide amniotique, du sang de cordon ombilical ou d'autres échantillons |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2010539479A true JP2010539479A (ja) | 2010-12-16 |
Family
ID=40452371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524888A Pending JP2010539479A (ja) | 2007-09-14 | 2008-09-15 | 月経液、子宮内膜／月経細胞、羊水、臍帯血又は他の試料の感染症検査 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2200620A4 (fr) |
| JP (1) | JP2010539479A (fr) |
| KR (1) | KR20100063089A (fr) |
| CN (1) | CN101854942A (fr) |
| AR (1) | AR068449A1 (fr) |
| AU (1) | AU2008299884A1 (fr) |
| BR (1) | BRPI0817333A2 (fr) |
| CA (1) | CA2699491A1 (fr) |
| CL (1) | CL2008002749A1 (fr) |
| CR (1) | CR11315A (fr) |
| EC (1) | ECSP10010048A (fr) |
| MX (1) | MX2010002910A (fr) |
| NI (1) | NI201000037A (fr) |
| TW (1) | TW200918020A (fr) |
| WO (1) | WO2009035706A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016523550A (ja) * | 2013-07-03 | 2016-08-12 | コイン アイピー ホールディングス、 エルエルシー | 化学的または生物学的物質に対する応答の予測方法 |
| AU2015302059B2 (en) | 2014-08-12 | 2020-02-06 | Nextgen Jane, Inc. | System and method for monitoring health based on collected bodily fluid |
| EP3442706A4 (fr) | 2016-04-13 | 2020-02-19 | NextGen Jane, Inc. | Dispositifs, systèmes et procédés de collecte et de conservation d'échantillon |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511078A (ja) * | 1996-05-17 | 2000-08-29 | エイ・エフイーエム・メディカル・コーポレーション | 診断目的のために膣の流体および剥離された膣細胞を収集する方法および装置 |
| US20050186111A1 (en) * | 2004-01-28 | 2005-08-25 | Naishu Wang | Interrupted flow rapid confirmatory immunological testing device and method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR065584A1 (es) * | 2007-03-01 | 2009-06-17 | Cryo Cell Internat Inc | Obtencion aislamiento y crioconservacion de celulas endometriales / menstruales |
-
2008
- 2008-09-15 AU AU2008299884A patent/AU2008299884A1/en not_active Abandoned
- 2008-09-15 AR ARP080103996A patent/AR068449A1/es not_active Application Discontinuation
- 2008-09-15 CL CL2008002749A patent/CL2008002749A1/es unknown
- 2008-09-15 BR BRPI0817333A patent/BRPI0817333A2/pt not_active IP Right Cessation
- 2008-09-15 WO PCT/US2008/010751 patent/WO2009035706A1/fr active Application Filing
- 2008-09-15 MX MX2010002910A patent/MX2010002910A/es not_active Application Discontinuation
- 2008-09-15 CN CN200880115990A patent/CN101854942A/zh active Pending
- 2008-09-15 KR KR1020107006492A patent/KR20100063089A/ko not_active Application Discontinuation
- 2008-09-15 TW TW097135378A patent/TW200918020A/zh unknown
- 2008-09-15 JP JP2010524888A patent/JP2010539479A/ja active Pending
- 2008-09-15 CA CA2699491A patent/CA2699491A1/fr not_active Abandoned
- 2008-09-15 EP EP08830729A patent/EP2200620A4/fr not_active Withdrawn
-
2010
- 2010-03-15 CR CR11315A patent/CR11315A/es not_active Application Discontinuation
- 2010-03-15 NI NI201000037A patent/NI201000037A/es unknown
- 2010-03-23 EC EC2010010048A patent/ECSP10010048A/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000511078A (ja) * | 1996-05-17 | 2000-08-29 | エイ・エフイーエム・メディカル・コーポレーション | 診断目的のために膣の流体および剥離された膣細胞を収集する方法および装置 |
| US20050186111A1 (en) * | 2004-01-28 | 2005-08-25 | Naishu Wang | Interrupted flow rapid confirmatory immunological testing device and method |
Non-Patent Citations (5)
| Title |
|---|
| JPN6012038916; ＡＹＯＯＬＡ Ｅ Ａ ｅｔ ａｌ．: 'Ａｎｔｉｂｏｄｙ ｔｏ ｈｅｐａｔｉｔｉｓ Ｂ ｃｏｒｅ ａｎｔｉｇｅｎ， ｅ-ａｎｔｉｇｅｎ ａｎｄ ｉｔｓ ａｎｔｉｂｏｄｙ ｉｎ ｍｅｎｓｔｒｕａｌ ｂｌｏｏｄ ａｎｄ ｓｅｍｅｎ' ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＧＹＮＥＣＯＬＯＧＹ ＡＮＤ ＯＢＳＴＥＴＲＩＣＳ Ｖｏｌ．１９，Ｎｏ． ３, 19810601, Ｐ．２２１-２２３ * |
| JPN6012038917; ＥＬ ＢＯＲＡＩ Ｎ ｅｔ ａｌ．: 'Ｄｅｔｅｃｔｉｏｎ ｏｆ ｈｅｒｐｅｓ ｓｉｍｐｌｅｘ ＤＮＡ ｉｎ ｓｅｍｅｎ ａｎｄ ｍｅｎｓｔｒｕａｌ ｂｌｏｏｄ ｏｆ ｉｎｄｉｖｉｄｕａｌｓ ａｔｔｅｎｄｉｎｇ ａｎ ｉｎｆｅｒｔｉｌｉｔｙ' ＴＨＥ ＪＯＵＲＮＡＬ ＯＦ ＯＢＳＴＥＴＲＩＣＳ ＡＮＤ ＧＹＮＡＥＣＯＬＯＧＹ ＲＥＳＥＡＲＣＨ Ｖｏｌ．２３，Ｎｏ． １, 1997, Ｐ．１７-２４ * |
| JPN6012038919; Ｃｏｎｓｔａｎｃｅｂ Ｗｏｆｓｙ ｅｔ ａｌ．: 'ＩＳＯＬＡＴＩＯＮ ＯＦ ＡＩＤＳ-ＡＳＳＯＣＩＡＴＥＤ ＲＥＴＲＯＶＩＲＵＳ ＦＲＯＭ ＧＥＮＩＴＡＬ ＳＥＣＲＥＴＩＯＮＳ ＯＦ ＷＯＭＥＮ ＷＩＴＨ ＡＮＴＩＢＯＤＩＥＳ ＴＯ ＴＨＥ ＶＩＲＵ' Ｔｈｅ Ｌａｎｃｅｔ Ｖｏｌ．３２７，Ｎｏ．８４８０, 19860301, Ｐ．５２７-５２９ * |
| JPN6012038921; ＪＩＡＮＧ ＸＩＵＧＡＯ ｅｔ ａｌ．: 'Ｓｐｅｃｉｆｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ Ｇ ａｎｔｉｂｏｄｙ ｄｅｔｅｃｔｅｄ ｉｎ ｕｍｂｉｌｉｃａｌ ｂｌｏｏｄ ａｎｄ ａｍｎｉｏｔｉｃ ｆｌｕｉｄ ｆｒｏｍ ａ ｐｒｅｇｎａｎｔ ｗｏ' ＣＬＩＮＩＣＡＬ ＡＮＤ ＤＩＡＧＮＯＳＴＩＣ ＬＡＢＯＲＡＴＯＲＹ ＩＭＭＵＮＯＬＯＧＹ Ｖｏｌ．１１，Ｎｏ． ６, 200411, Ｐ．１１８２-１１８４ * |
| JPN6012038922; ＡＹＯＯＬＡ Ｅ Ａ ｅｔ ａｌ．: 'Ｈｅｐａｔｉｔｉｓ Ｂ ｓｕｒｆａｃｅ ａｎｔｉｇｅｎ ｉｎ ｍｅｎｓｔｒｕａｌ ｂｌｏｏｄ ａｎｄ ｓｅｍｅｎ' ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＧＹＮＥＣＯＬＯＧＹ ＡＮＤ ＯＢＳＴＥＴＲＩＣＳ Ｖｏｌ．１８，Ｎｏ．３, 19800101, Ｐ．１８５-１８７ * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101854942A (zh) | 2010-10-06 |
| CR11315A (es) | 2010-08-13 |
| BRPI0817333A2 (pt) | 2017-06-13 |
| KR20100063089A (ko) | 2010-06-10 |
| NI201000037A (es) | 2011-06-21 |
| AR068449A1 (es) | 2009-11-18 |
| CL2008002749A1 (es) | 2010-05-07 |
| MX2010002910A (es) | 2010-05-24 |
| EP2200620A1 (fr) | 2010-06-30 |
| EP2200620A4 (fr) | 2010-10-27 |
| ECSP10010048A (es) | 2010-06-29 |
| CA2699491A1 (fr) | 2009-03-19 |
| AU2008299884A1 (en) | 2009-03-19 |
| WO2009035706A1 (fr) | 2009-03-19 |
| TW200918020A (en) | 2009-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3853317B2 (ja) | 複数感染症の同時検出診断キットおよびその製造方法 | |
| US20090104650A1 (en) | Infectious diseases testing of menstrual fluid, endometrial/menstrual cells, amniotic fluid, umbilical cord blood or other samples | |
| Voordouw et al. | Performance of Zika assays in the context of Toxoplasma gondii, parvovirus B19, rubella virus, and cytomegalovirus (TORCH) diagnostic assays | |
| FI90801C (fi) | Menetelmä anti-HIV:n määrittämiseksi, tarvikkeet sitä varten ja niiden käyttö tässä menetelmässä | |
| Chou et al. | Immunoglobulin M to cytomegalovirus in primary and reactivation infections in renal transplant recipients | |
| JP2010539479A (ja) | 月経液、子宮内膜／月経細胞、羊水、臍帯血又は他の試料の感染症検査 | |
| JPH0743384B2 (ja) | アッセイ用水性洗浄液、診断試験キット及び単純ヘルペスウイルスの測定方法 | |
| CN101368964A (zh) | 一种检测巨细胞病毒IgG抗体的化学发光法免疫分析诊断试剂盒 | |
| CN101368965A (zh) | 一种检测巨细胞病毒IgM抗体的化学发光法免疫分析诊断试剂盒 | |
| Griffiths | Cytomegalovirus and the liver | |
| CN116500260A (zh) | 免疫缺陷病毒抗原和抗体快速定性检测的试纸条、检测卡及检测方法 | |
| WO2008104081A1 (fr) | Dispositif de dosage immunologique parallèle | |
| EP1135684B1 (fr) | SPECIFICITE AMELIOREE DE LA DETECTION D'ANTICORPS IgM ANTIRUBEOLIQUES | |
| RU2310851C1 (ru) | Способ диагностики внутриутробных вирусных инфекций у детей | |
| Al-dorri | Estimation of some immunological biomarkers in aborted women infected with human cytomegalovirus (HCMV) in Salah Al-deen province | |
| RU134329U1 (ru) | Тест-набор для иммунологического анализа антител класса g возбудителей инфекций torch-группы | |
| CN212410606U (zh) | 一种血小板抗体特异性流式检测试剂盒 | |
| RU134328U1 (ru) | Тест-набор для иммунологического анализа антител класса м возбудителей инфекций torch-группы | |
| EP0302154A1 (fr) | Détection de VIH et d'anticorps antilymphocytes | |
| Tamym et al. | DETECTION OF CYTOMEGALO VIRUS ANTIBODY AND ANTIGEN AMONG PREGNANT AND REPEATED ABORTION WOMAN IN KHARTOM STATES | |
| Rathore et al. | STUDY OF DISTRIBUTION OF BLOOD GROUPS AND HAZARDS OF TRANSFUSION REACTIONS | |
| TO et al. | HUMAN IMMUNODEFICIENCY VIRUS TYPES 1 AND 2:(E. COLI, B. MEGATERIUM, RECOMBINANT ANTIGEN) HIVAB™ HIV-1/HIV-2 (rDNA) EIA | |
| BLOOD | HIV I&II TEST STRIP | |
| Kit | 96 Tests | |
| Abubakar Mustapha et al. | Descriptive Serological Diagnostic Techniques of HIV and AIDS Infections Amongst Adults Persons in Maiduguri, Nigeria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110915 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120725 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120726 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121220 |